Companies

Who we bring together sets us apart

Companies

    Our tenants span the life science sector, including therapeutics, diagnostics, medical devices, and research tools. They learn from and support each other, often forming partnerships.

    Scientists working
    Overview

    Get to know our tenants, the
    hardworking innovators at the
    core of our community.

    View our job listings

    Tenant Spotlights

     View all spotlights

    Learn more about
    their stories

    brad niles

    Tenant Spotlight on ARIZ: Rising to the Challenge to Make Cancer Treatments More Humane 

    Cancer treatments are often as grueling as the disease itself—chemotherapy can bring unbearable side effects like debilitating fatigue, nausea, and hair loss, leaving patients vulnerable and stripped of their identity. But what if cancer care could be better? More precise? Less harmful? Enter ARIZ Precision Medicine. Their mission is to revolutionize cancer care by developing therapies that not only fight the disease but also preserve the quality of life for patients. Learn how they’re doing this in our latest Tenant Spotlight. Read post
    Dart hits the bullseye

    ARIZ One of “Eight Nanotechnology Companies to Watch Out for”

    The company’s product is composed of a nanoparticle, which is customized based on the kind of cancer it is attacking, and has small interfering RNA (siRNA) that kill proteins that drive cancer without harming the neighboring healthy cells, cancer cell targeting peptides, as well as the chemotherapy drug – which is encapsulated within the nanoparticle. The nanoparticle is PEGylated, a process by which the polymer polyethylene glycol (PEG) is added to protect the drug. Read post
    The HOPO Therapeutics team in front of the Bakar Labs core facility

    HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity

    The funds will be used to advance development of the drug candidate HOPO-101 through registrational studies as a medical countermeasure against radiological threats, including planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The initial award of approximately $9.4 million will fund toxicology and pharmacology studies, manufacturing activities, and nonclinical research in other types of heavy metal poisoning, with approximately $216 million in additional funding available for later-stage development upon agreement between BARDA and HOPO. Read post
    aikium

    Tenant Spotlight on Aikium: A Trillion Shots at Targeting Tangled Proteins

    Aikium has essentially invented a new protein family. Called “SeqR” proteins, they are sequence specific binders that can be applied to different therapeutic needs such as cancer, neuro-inflammation, and some autoimmune disorders. Aikium is going after chemokine receptors, a subset of G-protein coupled receptors, a large class of molecules that have long proven difficult to target. By virtue of being on immune cells, they are front and center in cancer and immune-mediated diseases. Read post
    RVB cells delivering protein therapy continuously on skin

    NIH Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome

    ResVita Bio is pioneering continuous protein therapy, delivered through a genetically engineered probiotic platform that temporarily colonizes the skin and continuously releases therapeutic proteins, such as LEKTI, to inhibit protease activity. This continuous delivery method ensures high levels of the therapeutic agent at the site of damage, restoring the integrity of the skin barrier. This represents a significant shift from traditional therapies, which may not provide sustained treatment at the site of the disease. Read post
    Scientist
    Want to learn more?

    Become a tenant at Bakar Labs

    Get in touch